Broad Cross-Protection against H5N1 Avian Influenza Virus Infection by Means of Monoclonal Antibodies that Map to Conserved Viral Epitopes
Open Access
- 1 January 2009
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 199 (1) , 49-58
- https://doi.org/10.1086/594374
Abstract
Background. Passive immunization with human H5 antisera or H5-specific monoclonal antibodies (MAbs) has potential as an effective treatment for acuteKeywords
This publication has 42 references indexed in Scilit:
- Update on Avian Influenza A (H5N1) Virus Infection in HumansNew England Journal of Medicine, 2008
- The growth and potential of human antiviral monoclonal antibody therapeuticsNature Biotechnology, 2007
- Treatment with Convalescent Plasma for Influenza A (H5N1) InfectionNew England Journal of Medicine, 2007
- Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 InfluenzaPLoS Medicine, 2007
- WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virusPublished by Elsevier ,2007
- Lower Clinical Effectiveness of Oseltamivir against Influenza B Contrasted with Influenza A Infection in ChildrenClinical Infectious Diseases, 2007
- Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in miceRespiratory Research, 2006
- Distribution of Amantadine‐Resistant H5N1 Avian Influenza Variants in AsiaThe Journal of Infectious Diseases, 2006
- Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in miceRespiratory Research, 2006
- Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant VariantsAntimicrobial Agents and Chemotherapy, 2001